PR
PRME.CD
—
—
Pharmaceuticals & Medical Research
Prime Drink Group Corp
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$3,99
Open
$3,83
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Prime Drink Group Corp is a Canadian-based company primarily engaged in the production and distribution of alcoholic beverages, including craft beers and ciders, with a focus on the domestic market.
Business. Prime Drink Group Corp (PRME.CD) is a health care company operating within the pharmaceuticals and medical research industry. The firm generates revenue through the sale of products in this sector. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY13 analysts
10 buy3 hold0 sell
Avg 12m price target7,25
Analyst recommendations
13 analysts · consensus BuyBuy10
Hold3
Sell0
12-month price target
7,25
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
13 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to PRME.CD. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Prime Drink Group Corp (PRME.CD) is a health care company operating within the pharmaceuticals and medical research industry. The firm generates revenue through the sale of products in this sector. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDPrime Drink Group Corp has a fully diluted share count of 372,970,512, with no additional shares outstanding in the diluted scenario, indicating no immediate dilution risk from stock options or convertible instruments. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents, which limits the ability to evaluate its short-term financial stability.
Profitability and return metrics are not available in the current dataset, which prevents a direct comparison to industry benchmarks or preferred metrics for the Brewers industry. Without access to key financial ratios such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's operational efficiency or capital returns relative to its peers.
The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to evaluate the risk associated with over-reliance on specific markets or customer segments. In the absence of segmental or geographic breakdowns, the company's exposure to regional economic shifts or regulatory changes remains opaque.
Growth trajectory is also unclear, as the dataset does not include forward-looking revenue projections or historical growth rates. Without a clear picture of the company's past performance or future expectations, it is challenging to determine whether the company is expanding, contracting, or maintaining its market position.
The risk assessment highlights a lack of liquidity data and no identified dilution risk in the near term. However, the absence of balance-sheet inputs and the lack of going-concern language in the source documents raise concerns about the company's financial transparency and potential operational risks.
Recent events, including filings or transcripts, are not available in the dataset, which limits the ability to assess any material developments that may have occurred in the company's operations or strategic direction. The lack of recent disclosures or public statements further obscures the company's current status and future plans.
Key takeaways
- The company has no immediate dilution risk, as the diluted share count is equal to the basic share count.
- Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language in the source documents.
- Profitability and return metrics are not available, preventing a comparison to industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into market risk.
- Growth trajectory and recent strategic developments are unclear due to the absence of forward-looking data and event disclosures.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation FY
Market price
$0,06
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Cell & Gene Therapies—
low · llm_fanout_v2
Gene Editing Therapies—
low · llm_fanout_v2
Business relationships
Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries2
EX21:053ab611fc79EX21:053ab611fc79Subsidiarie97%
EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs PRME · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+206,8 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+118,6 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
+6,2 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+171,5 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+185,3 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+108,9 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 44 %
EPS
Consensus EPS
-0,99
Predicted surprise
-0,08
Beat probability
44 %
Analysts
13
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio -0,01 · as of 2026-07-07 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$4,25
Mean$7,25
Median$8,00
High$11,00
Spot$0,06
+11983.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 3 140 000 sh11 grants11 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
- Director · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
- Director, 10% owner · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
- Director · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
- Director · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
- Director · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
- Director · Stock Option (right to buy) → Common StockAcquired 75 000 @ $3,06grant · 2026-06-05
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 800 000 @ $3,67grant · 2026-04-16
- Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 1 300 000 @ $4,38grant · 2026-02-26
- Chief Technical Officer · Stock Option (right to buy) → Common StockAcquired 375 000 @ $3,34grant · 2026-02-23
- See Remarks · Stock Option (right to buy) → Common StockAcquired 140 000 @ $3,34grant · 2026-02-23
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Source documents
- Prime Drink Group Corp Market data — financials · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2024-06-300,00 %$26M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$22M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-12-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Keith M. GottesdienerPresident, Chief Executive Officer, Director
Insider activity
Net buying3 buys · 0 sellsnet $24,9M3 insiders · last 365d
- 10% owner · Common StockBought 3 030 300 @ $3,30$10,0M · 2025-08-01
- 10% owner · Common StockBought 1 500 000 @ $3,30$5,0M · 2025-08-01
- Director, 10% owner · Common StockBought 3 030 300 @ $3,30$10,0M · 2025-08-01
Short positioning
33.5Mshares short-3.4% vs prior
6.74days to cover
52.7%short of daily vol
480fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
PRME.CDCanonical
— · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): -166.4%Derived (calculated)
- Return on assets (FY 2025-12-31): -58.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.84xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.84xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -2.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 53.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -65.5%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -37.9%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -32.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -2.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -21.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 15.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 55.3%Derived (calculated)
- Net margin (FY 2025-12-31): -4,342.4%Derived (calculated)
- Total assets (annual): USD 342.73MSEC XBRL filing
- Operating cash flow (annual): USD -162.56MSEC XBRL filing
- Revenue (annual): USD 4.63MSEC XBRL filing
- Total operating expenses (annual): USD 212.98MSEC XBRL filing
- Cash & equivalents (annual): USD 63.03MSEC XBRL filing
- Capex (annual): USD 4.53MSEC XBRL filing
- Current liabilities (annual): USD 37.45MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-05 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative
2026-06-05INSIDERCahill Thomas acquired 75.0k sh Stock Option (right to buy) — Director
2026-06-05INSIDERFoster-Cheek Kaye I acquired 75.0k sh Stock Option (right to buy) — Director
2026-06-05INSIDERChung Wendy acquired 75.0k sh Stock Option (right to buy) — Director
2026-06-05INSIDERSchenkein David P acquired 75.0k sh Stock Option (right to buy) — Director
2026-06-05INSIDERMarrazzo Jeffrey D acquired 75.0k sh Stock Option (right to buy) — Director
2026-06-05INSIDERNELSEN ROBERT acquired 75.0k sh Stock Option (right to buy) — Director, 10% owner
2026-06-05INSIDERKelly Michael Aaron acquired 75.0k sh Stock Option (right to buy) — Director
2026-04-16 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
2026-04-16INSIDERMakhni Svetlana Ni acquired 800.0k sh Stock Option (right to buy) — Chief Financial Officer
2026-02-26 00:00 UTCINSIDER3 insider transactions — 2026-02 3 derivative
2026-02-26INSIDERReine Allan acquired 1.30M sh Stock Option (right to buy) — Director, Chief Executive Officer
2026-02-23INSIDERLEE ANN L. acquired 375.0k sh Stock Option (right to buy) — Chief Technical Officer
2026-02-23INSIDERAlenson Carman acquired 140.0k sh Stock Option (right to buy) — See Remarks
2025-08-01 00:00 UTCINSIDER55 insider transactions — 2025-08 · net buy $24.9M 52 derivative
2025-08-01INSIDERARCH Venture Partners XII, LLC bought 3.03M sh — 10% owner ~$10.00M
2025-08-01INSIDERGV 2021 GP, L.L.C. bought 1.50M sh — 10% owner ~$4.95M
2025-08-01INSIDERNELSEN ROBERT bought 3.03M sh — Director, 10% owner ~$10.00M
2025-08-01INSIDERKelly Michael Aaron acquired 9.0k sh Stock Option (right to buy) — Director
2025-08-01INSIDERLEE ANN L. disposed of 181.0k sh Stock Option (right to buy) — Chief Technical Officer
2025-08-01INSIDERLEE ANN L. acquired 181.0k sh Stock Option (right to buy) — Chief Technical Officer
2025-08-01INSIDERSchenkein David P disposed of 39.1k sh Stock Option (right to buy) — Director
2025-08-01INSIDERSchenkein David P acquired 39.1k sh Stock Option (right to buy) — Director
2025-08-01INSIDERSchenkein David P disposed of 45.0k sh Stock Option (right to buy) — Director
2025-08-01INSIDERSchenkein David P acquired 45.0k sh Stock Option (right to buy) — Director
2025-08-01INSIDERNELSEN ROBERT disposed of 39.1k sh Stock Option (right to buy) — Director, 10% owner
Showing the 40 most recent of 46 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage